Best Practice & Research Clinical Haematology
Volume 21, Issue 2 , Pages 119-128 , June 2008

The thymus in GVHD pathophysiology

  • Werner Krenger, PhD (Independent Investigator in Molecular Medicine)
    • ,
  • Georg A. Holländer, MD (Head Research, University Children's Hospital)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +41 61 695 3069; Fax: +41 61 695 3070.

References 

  1. Hakim FT, Mackall CL. The immune system: effector and target of graft-versus-host disease. In:  Ferrara JLM,  Deeg HJ,  Burakoff SJ editor. Graft-vs-host disease. New York: Marcel Dekker, Inc.; 1997;p. 257–289
  2. Haynes BF, Markert ML, Sempowski GD, et al. The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. Annual Review of Immunology. 2000;18:529–560
  3. Weinberg K, Blazar BR, Wagner JE, et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood. 2001;97:1458–1466
  4. Hakim FT, Gress RE. Reconstitution of thymic function after stem cell transplantation in humans. Current Opinion in Hematology. 2002;9:490–496
  5. Van den Brink MR, Alpdogan O, Boyd RL. Strategies to enhance T-cell reconstitution in immunocompromised patients. Nature Reviews. Immunology. 2004;4:856–867
  6. Antin JH. Immune reconstitution: the major barrier to successful stem cell transplantation. Biology of Blood and Marrow Transplantation. 2005;11:43–45
  7. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annual Review of Immunology. 2007;25:139–170
  8. Douek DC, Vescio RA, Betts MR, et al. Assessment of thymic output in adults after hematopoietic stem cell transplantation and prediction of T-cell reconstitution. Lancet. 2000;355:1875–1881
  9. Patel DD, Gooding ME, Parrott RE, et al. Thymic function after hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. The New England Journal of Medicine. 2000;342:1325–1332
  10. Weinberg KI. Protection from posttransplantation immune deficiency?. Blood. 2007;109:3617–3618
  11. Gill J, Malin M, Sutherland J, et al. Thymic generation and regeneration. Immunological Reviews. 2003;195:28–50
  12. Van Ewijk W, Wang B, Holländer G, et al. Thymic microenvironments, 3-D versus 2-D?. Seminars in Immunology. 1999;11:57–64
  13. Rossi S, Blazar BR, Farrell CL, et al. Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease. Blood. 2002;100:682–691
  14. Rossi SW, Jeker LT, Ueno T, et al. Keratinocyte growth factor (KGF) enhances postnatal T-cell development via enhancements in proliferation and function of thymic epithelial cells. Blood. 2007;109:3803–3811
  15. Holländer GA, Wang B, Nichogiannopoulou A, et al. Developmental control point in induction of thymic cortex regulated by a subpopulation of prothymocytes. Nature. 1995;373:350–353
  16. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature. 1998;396:690–695
  17. Ochs L, Shu XO, Miller J, et al. Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients. Blood. 1995;86:3979–3986
  18. Bacigalupo A. Management of acute graft-versus-host disease. British Journal of Haematology. 2007;137:87–98
  19. Shlomchik WD. Graft-versus-host disease. Nature Reviews. Immunology. 2007;7:340–352
  20. Krenger W, Ferrara JLM. Graft-versus-host disease and the Th1/Th2 paradigm. Immunologic Research. 1996;15:50–73
  21. Krenger W, Hill GR, Ferrara JLM. Cytokine cascades in acute graft-versus-host disease. Transplantation. 1997;64:553–558
  22. Blazar BR, Murphy WJ. Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD). Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 2005;360:1747–1767
  23. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Seminars in Hematology. 2006;43:3–10
  24. Hauri-Hohl MM, Keller MP, Gill J, et al. Donor T-cell alloreactivity against host thymic epithelium limits T-cell development after bone marrow transplantation. Blood. 2007;109:4080–4088
  25. Van den Brink MR, Moore E, Ferrara JL, et al. Graft-versus-host-disease-associated thymic damage results in the appearance of T cell clones with anti-host reactivity. Transplantation. 2000;69:446–449
  26. Beschorner WE, Hutchins GM, Elfenbein GJ, et al. The thymus in patients with allogeneic bone marrow transplants. The American Journal of Pathology. 1978;92:173–181
  27. Seemayer TA, Lapp WS, Bolande RP. Thymic epithelial injury in graft-versus-host reactions following adrenalectomy. The American Journal of Pathology. 1978;93:325–338
  28. Fukushi N, Arase H, Wang B, et al. Thymus: a direct target tissue in graft-versus-host reaction after allogeneic bone marrow transplantation that results in abrogation of induction of self-tolerance. Proceedings of the National Academy of Sciences of the United States of America. 1990;87:6301–6305
  29. Lewin SR, Heller G, Zhang L, et al. Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantation. Blood. 2002;100:2235–2242
  30. Talvensaari K, Clave E, Douay C, et al. A broad T-cell repertoire diversity and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation. Blood. 2002;99:1458–1464
  31. Poulin JF, Sylvestre M, Champagne P, et al. Evidence for adequate thymic function but impaired naive T-cell survival following allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease. Blood. 2003;102:4600–4607
  32. Storek J, Joseph A, Espino G, et al. Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. Blood. 2001;98:3505–3512
  33. Hochberg EP, Chillemi AC, Wu CJ. Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation. Blood. 2001;98:1116–1121
  34. Krenger W, Schmidlin H, Cavadini G, et al. On the relevance of T-cell receptor rearrangement circles (TRECs) as molecular markers for thymic output during experimental graft-versus-host disease. Journal of Immunology. 2004;172:7359–7367
  35. Krenger W, Rossi S, Holländer GA. Apoptosis of thymocytes during acute graft-versus-host disease is independent of glucocorticoids. Transplantation. 2000;69:2190–2193
  36. Krenger W, Rossi S, Piali L, et al. Thymic atrophy in murine acute graft-versus-host disease is effected by impaired cell cycle progression of host pro- and pre-T cells. Blood. 2000;96:347–354
  37. Desbarats J, Lapp WS. Thymic selection and thymic major histocompatibility complex class II expression are abnormal in mice undergoing graft-versus-host reactions. The Journal of Experimental Medicine. 1993;178:805–814
  38. Adkins B, Gandour D, Strober S, et al. Total lymphoid irradiation leads to transient depletion of the mouse thymic medulla and persistent abnormalities among medullary stromal cells. Journal of Immunology. 1988;140:3373–3379
  39. Van Vliet E, Melis M, Van Ewijk W. The influence of dexamethasone treatment on the lymphoid and stromal composition of the mouse thymus: a flow cytometric and immunohistological analysis. Cellular Immunology. 1986;103:229–240
  40. Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. The New England Journal of Medicine. 1995;332:143–149
  41. Anderson MS, Venanzi ES, Chen Z, et al. The cellular mechanism of Aire control of T cell tolerance. Immunity. 2005;23:227–239
  42. Pereira LE, Bostik P, Ansari AA. The development of mouse APECED models provides new insight into the role of AIRE in immune regulation. Clinical & Developmental Immunology. 2005;12:211–216
  43. Fry T, Mackall CL. Interleukin-7: from bench to clinic. Blood. 2002;99:3892–3904
  44. Sutherland JS, Goldberg GL, Hammett MV, et al. Activation of thymic regeneration in mice and humans following androgen blockade. Journal of Immunology. 2005;175:2741–2753
  45. Finch PW, Rubin JS. Keratinocyte growth factor/fibroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair. Advances in Cancer Research. 2004;69–115
  46. Blazar BR, Weisdorf DJ, DeFor TE, et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood. 2006;108:3216–3222
  47. Chu JW, Hakim FT. KGF boosts thymic architecture. Blood. 2007;109:3613–3614
  48. Guo L, Degenstein L, Fuchs E. Keratinocyte growth factor is required for hair development but not for wound healing. Genes & Development. 1996;10:165–175
  49. Revest JM, Suniara RK, Kerr K, et al. Development of the thymus requires signaling through the fibroblast growth factor receptor r2-IIIb. Journal of Immunology. 2001;167:1954–1961

PII: S1521-6926(08)00002-9

doi: 10.1016/j.beha.2008.02.001

Best Practice & Research Clinical Haematology
Volume 21, Issue 2 , Pages 119-128 , June 2008

Article Tools